Hyperhidrosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hyperhidrosis, a condition marked by excessive sweating, arises from the overstimulation of cholinergic receptors on eccrine glands. This disorder stands out by causing sweat production beyond what is necessary for maintaining a stable body temperature. Eccrine glands are most concentrated in axillae, palms, soles, and faces, making these regions the primary sites linked with hyperhidrosis. The malfunctioning of the acetylcholine negative feedback loop in these individuals is likely responsible for the shift from a normal physiological response to an abnormal pathological one. It is categorized into primary and secondary forms, each demanding distinct approaches to management and treatment. The primary variant typically emerges earlier in life and is characterized by more localized symptoms. On the other hand, the secondary type usually arises due to medication side effects or systemic conditions, particularly those involving the nervous system. Classification of hyperhidrosis into primary or secondary is crucial because the treatment strategies significantly differ between these two groups. Despite various literature reviews, the exact cause of primary hyperhidrosis remains unknown. Genetic factors are thought to contribute to excessive neural stimulation, although the mechanism is not fully comprehended. Identifying secondary causes is generally easier, as they are associated with medications like dopamine agonists, selective serotonin reuptake inhibitors (SSRIs), antipsychotics, and insulin, as well as systemic disorders including diabetes mellitus, hyperthyroidism, Parkinson's disease, and other neurological conditions, and even tumors like pheochromocytoma and lymphoma. It can be prompted by almost any febrile illness, chronic alcohol misuse, and tuberculosis. The development of segmental or localized hyperhidrosis is uncommon but can occur in areas like the forehead, axilla, palms, feet, or forearms in certain adults. Postmenopausal women might also experience moderate to severe hyperhidrosis around their face and scalp. Eccrine sweat glands receive sympathetic innervation through cholinergic fibers, which trigger impulses in response to the body's temperature control needs during physical or psychological stress. The hypothalamus's thermoregulatory center influences the sweat glands through sympathetic innervation. The activation of muscarinic receptors by cholinergic stimulation induces sweating. In cases of hyperhidrosis, the sympathetic nervous system becomes hyperactive, leading to excessive acetylcholine release from nerve endings. It is hypothesized that the negative feedback mechanism to the hypothalamus might be compromised, causing the body to sweat excessively for cooling. This pathological response can be prompted by medications that enhance acetylcholine release or systemic medical conditions that heighten sympathetic responses. Various topical and systemic agents are available for treating hyperhidrosis. Initial treatment usually involves using over-the-counter aluminum chloride hexahydrate at 20% concentration for 3 to 4 nights and as needed on subsequent nights. A recent addition to the treatment options is topical glycopyrronium tosylate, a premoistened cloth containing a 2.4% glycopyrronium solution. Hyperhidrosis has a guarded prognosis. While it's not life-threatening, it can lead to cosmetic concerns and even work-related difficulties. People with severe hyperhidrosis often experience a diminished quality of life.

·       The prevalence of hyperhidrosis is approximately 4.8%, encompassing around 15.3 million individuals in the United States. Among them, 70% report experiencing severe excessive sweating in at least one body area.

Thelansis’s “Hyperhidrosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperhidrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Hyperhidrosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hyperhidrosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hyperhidrosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032